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ABSTRACT
Background: Companion diagnostics aim to identify patients that will respond 
to targeted therapies, therefore increasing the clinical efficacy of such drugs. Less is 
known about their influence on safety and tolerability of targeted anti-cancer agents.
Methods and findings: Randomized trials evaluating targeted agents for solid 
tumors approved by the US Food and Drug Administration since year 2000 were 
assessed. Odds ratios (OR) and and 95% confidence intervals (CI) were computed for 
treatment-related death, treatment-discontinuation related to toxicity and occurrence 
of any grade 3/4 adverse events (AEs). The 12 most commonly reported individual 
AEs were also explored. ORs were pooled in a meta-analysis. Analysis comprised 
41 trials evaluating 28 targeted agents. Seventeen trials (41%) utilized companion 
diagnostics. Compared to control groups, targeted drugs in experimental arms were 
associated with increased odds of treatment discontinuation, grade 3/4 AEs, and toxic 
death irrespective of whether they utilized companion diagnostics or not. Compared 
to drugs without available companion diagnostics, agents with companion diagnostics 
had a lower magnitude of increased odds of treatment discontinuation (OR = 1.12 
versus 1.65, p < 0.001) and grade 3/4 AEs (OR = 1.09 versus 2.10, p < 0.001), but 
no difference in risk of toxic death (OR = 1.40 versus 1.27, p = 0.69). Differences 
between agents with and without companion diagnostics were greatest for diarrhea 
(OR = 1.29 vs. 2.43, p < 0.001), vomiting (OR = 0.86 vs. 1.44, p = 0.005), cutaneous 
toxicity (OR = 1.82 vs. 3.88, p < 0.001) and neuropathy (OR = 0.64 vs. 1.60, p < 
0.001).
Conclusions: Targeted drugs with companion diagnostics are associated with 
improved safety, and tolerability. Differences were most marked for gastrointestinal, 
cutaneous and neurological toxicity.
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INTRODUCTION
The aim of personalizing cancer treatments by 
targeting genomic alterations in the tumor has seen 
rapid advances in recent years [1]. Knowledge of the 
molecular mechanisms associated with cancer initiation 
and progression has recently improved with the increasing 
use of molecular techniques such as gene sequencing [1, 
2]. This knowledge has permitted the identification of 
alterations in cancer cells and the subsequent development 
of therapeutic agents targeting these alterations [3, 4]. 
Central to the drive for personalized medicine is the 
need to develop and validate specific diagnostic tests 
that facilitate the identification of patients that are most 
likely to respond to a given treatment [5]. Such tests 
have been named companion diagnostics and are defined 
by the US Food and Drug Administration (FDA) as in 
vitro diagnostic devices that provide information that is 
essential for the safe and effective use of a corresponding 
therapeutic product [6]. A companion diagnostic is a pre-
treatment predictor of benefit that is expected to allow 
selection of patients with a biomarker predicting greater 
efficacy from a given therapy compared to patients 
without the biomarker treated with the same drug. In 
parallel with the development of companion diagnostics, 
the identification of tumors where specific molecular 
alterations are ubiquitous has also permitted the design and 
evaluation of agents targeting these molecular alterations 
[4]. This has been the case for agents targeting c-kit in 
gastrointestinal stromal tumors (GIST) [7-8] or RET in 
medullary thyroid cancer [9, 10].
Some companion diagnostics have been developed 
using retrospective analyses of clinical studies [11-12] 
while others have been developed synchronously with the 
related experimental drug and have been incorporated in 
multiples steps of the drug development process, including 
randomized controlled trials (RCTs) [5]. Presently, there 
are few targeted drugs in clinical development that do 
not have an associated biomarker discovery program to 
identify a specific companion diagnostic [5]. Despite 
these advances, little is known about the influence of 
the availability of companion diagnostics on safety and 
tolerability of targeted agents. 
Here, we aimed to evaluate the impact of 
incorporating companion diagnostics in randomized 
controlled trials (RCTs) of targeted agents that were 
used for the approval of new drugs since 2000. We 
hypothesized that the identification of responding patients 
by using companion diagnostics would be associated with 
not only increased magnitude of clinical benefit but also 
reduced toxicity compared to targeted agents without 
accompanying diagnostic tests. 
RESULTS
We identified 28 different targeted anti-cancer agents 
approved by the US FDA for 15 different indications 
between January 2000 and April 2014. These agents were 
evaluated in 41 separate trials. Seventeen trials (41%) 
were categorized as having a companion diagnostic 
(including 4 studies in tumors with ubiquitous molecular 
alterations, see Figure 1). Characteristics of included 
studies are shown in Table 1 and a list of drugs, their 
licensed indications and subgroup category is shown in 
Supplementary Table 1. Studies of drugs with companion 
diagnostics generally had lower sample sizes (Mann-
Whitney U p = 0.03) and were more likely to use PFS 
rather than OS as the primary endpoint (Mann-Whitney 
U p = 0.01). A non-significantly higher proportion of 
studies of targeted drugs with companion diagnostics 
led to accelerated approval by the FDA compared with 
regular approval (Mann-Whitney U p = 0.18). A list of 
FDA approved diagnostic tests identified in our search is 
shown in Supplementary Table 2. 
Among the 13 RCTs with companion diagnostics 
(excluding studies in tumors with ubiquitous molecular 
alterations), 11 studies (85%) utilized prospective 
development of the diagnostic test in the RCT, while in 2 
studies [11, 12] the companion diagnostic was developed 
retrospectively. In 11 RCTs (85%), the companion 
diagnostic comprised measurement of a mutation of which 
the protein product was an oncogenic target associated 
with favourable response to the experimental drug. 
Conversely, in 2 studies (15%) [11, 12] the diagnostic 
test identified patients with unfavourable responses 
to the investigational agent. Companion diagnostics 
associated with favourable drug responses comprised 
genomic alterations in non-small cell lung cancer (EGFR 
mutations and ALK rearrangements), breast and gastric 
cancers (HER2/neu amplification or overexpression), and 
in melanoma (B-RAF mutation). Companion diagnostics 
associated with resistance to the experimental drug were 
for mutations of the K-RAS gene in colon cancer.
Impact of companion diagnostics on efficacy
Data on OS and PFS were available from 39 and 
41 studies respectively. Compared to agents used in 
control groups, targeted drugs used in experimental arms 
of included trials showed improved PFS and OS. The 
magnitude of improvement in OS between targeted drugs 
in experimental groups and agents used in control groups 
was similar for targeted drugs with companion diagnostics 
and those without companion diagnostic tests (HR 0.71, 
95% CI 0.63-0.80 vs. HR 0.78, 95% CI 0.75-0.82, p for 
difference = 0.13, Figure 2B). When studies for conditions 
with ubiquitous molecular alterations or mutations [7-10] 
were excluded, there remained no difference between 
studies with companion diagnostics and those without (HR 
0.70, 95% CI 0.61-0.80 vs. HR 0.78, 95% CI 0.75-0.82, p 
for difference = 0.11). 
In contrast, agents with an available companion 
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Table 1: Characteristics of included studies. 
Characteristic
Companion 
Diagnostics
(n=17)
Non-companion 
Diagnostics
(n=24)
Sample size
 Median
 Range
 
347
199-1217
 
637
171-1226
Disease Site
 Breast Cancer
 Colorectal Cancer
 Non-small cell lung cancer
 Melanoma
 Renal cell carcinoma 
 Medullary thyroid cancer
 Gastrointestinal Stomal Tumor
 Other
 
4 (24%)
2 (12%)
3 (18%)
3 (18%)
0 (0%)
2 (12%)
2 (12%)
1 (6%)
 
2 (8%)
7 (29%)
2 (8%)
0 (0%)
6 (25%)
0 (0%)
0 (0%)
7 (29%)
Primary Endpoint
 Overall survival
 Progression-free survival or time to progression
 
3 (18%)
14 (82%)
 
14 (58%)
10 (42%)
Cross-over 6 (35%) 6 (25%)
Quality of life reported 4 (24%) 13 (54%)
Type of FDA approval
 Regular
 Accelerated
 
11 (65%)
6 (35%)
 
20 (83%)
4 (17%)
Figure 1: Flow diagram for identification and inclusion of studies.
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Table 2:  Differences in odds of individual grade 3/4 AEs between studies with available companion diagnostics and 
those without companion diagnostics. AEs, adverse events, CI, confidence interval; OR, odds ratio
Adverse event
Companion Diagnostics No Companion Diagnostics
P for 
difference
Number of 
included 
studies
OR 95% CI
Number of 
included 
studies
OR 95% CI
Anemia 8 0.79 0.62-1.00 12 1.14 0.89-1.46 0.04
Neutropenia 10 0.39 0.33-0.44 10 1.40 1.20-1.63 <0.001
Thrombocytopenia 5 5.18 3.09-8.66 12 1.66 1.23-2.22 <0.001
Diarrhea 14 1.29 1.07-1.55 22 2.43 2.08-2.83 <0.001
Vomiting 9 0.86 0.65-1.14 20 1.44 1.14-1.83 0.005
Stomatitis 7 1.53 0.78-3.02 14 2.59 2.01-3.33 0.16
Cutaneous toxicity 11 1.82 1.45-2.28 18 3.88 3.06-4.94 <0.001
Asthenia/Fatigue 14 0.99 0.79-1.23 24 1.23 1.11-1.37 0.07
Pulmonary/Dyspnea 6 1.15 0.84-1.57 11 0.90 0.74-1.09 0.19
Hypertension 5 5.95 3.03-11.67 14 5.87 4.74-7.26 0.97
Cardiac 4 1.57 1.11-2.23 3 6.88 1.25-37.82 0.10
Neuropathy 3 0.64 0.40-1.01 3 1.60 1.20-2.12 <0.001
Figure 2: Forest plot for progression free survival (A) and overall survival (B).
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Table 3: Sensitivity analyses for the effect of availability of companion diagnostics on adverse events. AEs, adverse 
events; CI, confidence interval; N, number; OR, odds ratio. NE, not estimatable.
Group N
Companion 
Diagnostic
Non-Companion 
Diagnostic P for 
difference
OR 95% CI OR 95% CI
Toxic death
Blinded companion [8-10, 24]
vs non-Companion
[25-38]
18 1.12 0.59 - 2.14 1.29 0.97 - 1.72 0.69
Open-label companion [39-45] 
vs non-Companion [46-52] 14 1.57 0.98 - 2.51 1.24 0.82 - 1.86 0.46
Best supportive care companion 
vs non-Companion [46, 47] 2 NE NE 1.02 0.45 - 2.31 NE
Placebo-control only control group companion [8-
10]
vs non-Companion [26-28, 30, 32,33] [34-37]
13 1.58 0.64 - 3.9 1.25 0.89 - 1.74 0.63
Active Treatment control group companion [24, 39-
45]
vs non-Companion [25-26, 29, 31, 48-52]
17 1.36 0.9 - 2.07 1.36 0.95 - 1.96 0.99
Active Treatment + Placebo control group 
companion [24]
vs non-Companion [25-26, 29, 31]
4 0.78 0.31 - 1.98 1.3 0.7 - 2.39 0.37
Treatment discontinuation
Blinded companion [7-10, 24]
vs non-Companion [25-38, 53] 20 1.57 1.09 - 2.26 1.97 1.71 - 2.28 0.25
Open-label companion[40-45, 54-56]
vs non-Companion[46-51, 57-58] 17 1.04 0.87 - 1.23 1.22 1.02 - 1.47 0.19
Best supportive care companion vs non-Companion 
[46-47,58] 3 NE NE 18.18 3.51 - 94.19 NE
Placebo-control only control group companion [8-
10], 
vs non-Companion [26-28, 30, 32-37]
14 1.85 1.16 - 2.94 1.90 1.56 - 2.32 0.91
Active Treatment control group companion [24,40-
45,54-56]
vs non-Companion [25, 29, 31, 38, 48-51, 53,57]
20 1.04 0.88 - 1.23 1.46 1.27 - 1.68 0.002
Active Treatment + Placebo control group 
companion [24]
vs non-Companion [25-26, 29, 31]
6 1.13 0.61 - 2.09 2.06 1.67 - 2.54 0.07
Any G3/4 AEs
Blinded companion [7-9]
vs non-Companion [26-33, 35, 53] 13 3.05 2.26 - 4.12 2.26 1.99 - 2.57 0.07
Open-label companion [42-43, 45]
vs non-Companion [49, 57] 5 0.68 0.56 - 0.83 1.57 1.21 - 2.03 <0.001
Best supportive care companion vs non-Companion 0 NE NE NE NE NE
Placebo-control only control group companion [7-9] 
vs non-Companion [26-28, 30, 32-33, 35] 10 3.05 2.26 - 4.12 2.26 1.9 - 2.69 0.09
Active Treatment control group companion [42-43, 
45] 
vs non-Companion [29, 31, 49, 53, 57]
8 0.68 0.56 - 0.83 1.99 1.71 - 2.32 <0.001
Active Treatment + Placebo control group 
companion vs non-Companion [29, 31] 3 NE NE 2.26 1.87 - 2.73 NE
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diagnostic were associated with a higher magnitude of 
benefit for PFS compared to agents without companion 
diagnostic tests (HR 0.43, 95% CI 0.37-0.51 vs. 0.53, 
95% CI 0.45-0.54, p for difference = 0.04, Figure 2A). 
However, this effect was lost after excluding agents used 
for conditions with ubiquitous activation of specific 
molecular pathways [7-10] (HR 0.47, 95% CI 0.40-0.55 
vs. 0.53, 95% CI 0.45-0.54, p for difference = 0.20). 
Impact of companion diagnostics on safety and 
tolerability
Data on toxic death, treatment discontinuation 
and any grade 3/4 AEs were available from 32, 37 and 
18 studies, respectively. Compared to agents used in 
control groups, targeted drugs used in experimental arms 
of included trials showed an increase in toxic death, 
treatment discontinuation and grade 3/4 AEs. Availability 
of companion diagnostics did not affect the magnitude 
of toxic death (OR 1.40, 95% CI 0.96-2.04 vs. 1.27, 
95% CI 1.01-1.61, p for difference = 0.69, Figure 3A). 
However, availability of companion diagnostics was 
associated with lower odds of treatment discontinuation 
(OR 1.12, 95% CI 0.96-1.31 vs. 1.65, 95% CI 1.47-1.84, 
p for difference < 0.001, Figure 3B) and any grade 3/4 
AEs (OR 1.09, 95% CI 0.93-1.28 vs. 2.10, 95% CI 1.88-
2.36, p for difference < 0.001, Figure 3C). Differences 
between drugs with companion diagnostics and those 
without for individual grade 3/4 AEs are shown in Table 
2. Companion diagnostics were associated with lower 
odds of anemia, neutropenia, diarrhea, vomiting, fatigue/
asthenia, dyspnea, neuropathy and skin AEs; similar odds 
of stomatitis, hypertension, pulmonary and cardiovascular 
AEs and higher odds of thrombocytopenia. Sensitivity 
analyses restricting studies based on blinding and type of 
control group are shown in Table 3. Sensitivity analyses 
did not show substantial differences in the results. There 
remained no difference in the odds of toxic death between 
agents with companion diagnostics and those without in 
all subgroups. Furthermore, the magnitude and direction 
of effect for treatment discontinuation was similar among 
subgroups as it was in the analysis of all included studies. 
However, lower odds of grade 3/4 AEs were not observed 
among blinded studies or in placebo controlled only 
control groups. Of interest, among the minority of studies 
reporting quality of life, studies utilizing companion 
diagnostics were more likely to report improved quality 
of life compared to those with companion diagnostics 
(Mann-Whitney U p = 0.03).
DISCUSSION
The presence of heterogeneity within histologically 
defined tumors means that the ability to identify 
subpopulations of patients who are more likely to benefit 
from a certain treatment is crucial [13]. Advances in 
the understanding of cancer biology have permitted the 
identification of molecular alterations that can be used 
for patient selection; both by ascertaining molecular 
alterations that are amenable to pharmacological 
intervention or by characterizing markers of resistance 
to specific therapy. In recent years, numerous targeted 
drugs have been approved for use in solid tumors. Some 
of these were approved with an accompanying companion 
diagnostic test allowing for identification of responsive or 
unresponsive patients while others were registered in less 
selected populations. Despite the increasing use of targeted 
agents and diagnostic tests to aid in personalization of 
Figure 3: Forest plot for toxic death (A), treatment discontinuation (B) and grade 3/4 AEs (C).
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therapy, there remain little data to inform of the impact of 
the availability of companion diagnostics on the efficacy, 
safety and tolerability of approved targeted anti-cancer 
drugs. Specifically, it is unclear if targeted agents with 
available companion diagnostics allow for both improved 
efficacy and toxicity compared to targeted agents used in 
unselected cancer patients. 
As expected, we have shown that availability 
of companion diagnostics is associated with modest 
improvements in efficacy of targeted anti-cancer drugs. 
Compared to treatment administered in control groups 
of RCTs, use of experimental targeted treatment with 
a companion diagnostic led to greater improvements 
in PFS than for experimental targeted agents without 
accompanying tests. However, the availability of 
companion diagnostics did not appear to influence the 
magnitude of benefit in OS; targeted agents with and 
without these tests showed similar improvements in 
pooled HR for OS. 
Of interest, our data showed generally better safety 
and tolerability for experimental targeted treatment with 
a companion diagnostic compared to targeted agents 
without accompanying tests. Consistent with data reported 
previously [14, 15], we observed that newly approved 
targeted drugs were generally associated with higher odds 
of toxic death, treatment discontinuation due to toxicity 
and both overall grade 3/4 AEs as well as individual 
grade 3/4 AEs. However, availability of companion 
diagnostics was associated with a lower magnitude of 
increase in the majority of these safety and tolerability 
parameters. Additionally, studies with companion 
diagnostics were more likely to report favorable changes 
in quality of life. These results suggest that targeted 
drugs developed with companion diagnostics may have 
a more favorable therapeutic index than targeted drugs 
without such accompanying tests. There are a number 
of possible reasons for this finding. First, the availability 
of a companion diagnostic may allow for lower doses of 
targeted drugs to be used in more responsive patients. 
Second, receipt of more efficacious drugs may lead to 
reduced tumor burden or improved performance status 
thereby leading to a lower frequency of AEs. Of note, 
differences in grade 3/4 AEs between targeted drugs with 
companion diagnostics and targeted drugs without these 
tests were not consistently observed in both blinded and 
open-label studies suggesting that some of the effect may 
relate to either subject or observer bias. However, no such 
findings were observed for treatment discontinuation 
suggesting that some of the differences in safety and 
tolerability parameters are likely true.
The availability of a companion diagnostic was 
also associated with differences in clinical trial design. 
RCTs utilizing companion diagnostics had smaller 
sample sizes. The reason for this finding is unclear, but 
may be explained by the greater magnitude of anticipated 
benefit resulting from enriching the study population with 
patients more likely to benefit from the experimental drug. 
Another explanation is the increased use of intermediate 
endpoints such as PFS, which was seen with studies 
utilizing companion diagnostics. No differences were 
observed for other parameters such as whether RCTs were 
used to support accelerated rather than regular approval, 
allowance of cross over or reporting of quality of life. 
The value of companion diagnostics as predictive 
markers appears clear. However, only a minority of 
approved targeted drugs have been developed with 
such diagnostic tests. The development of companion 
diagnostics in solid tumors is complex and has many 
challenges. Access to tissue for molecular characterization 
is guaranteed generally only at diagnosis and attempts to 
collect tissue at multiple time points after exposure to 
experimental therapy are limited by concerns about slower 
patient enrolment and insufficient research infrastructure 
to obtain and process tumor samples for molecular 
analysis. There has also been reluctance of the scientific 
community to design studies with mandatory repeated 
tissue collection [16]. This may explain why many 
biomarker programs embedded in RCTs do not lead to the 
identification of robust predictive markers.
This study has limitations. First we focused on 
RCTs, which were used to support registration with the 
US FDA. While this is a pragmatic and clinically relevant 
inclusion criterion, there may have been negative studies 
with companion diagnostics and their exclusion may have 
affected the observed difference in effect size for efficacy, 
safety and tolerability. It is likely that this may have led 
to enrichment for agents with a more favorable balance 
between efficacy and toxicity. Second, assessment of 
efficacy was based only on relative differences in OS or 
PFS between groups. Substantial differences in relative 
measures of efficacy do not necessarily translate into large 
differences in absolute benefits. Third, only 18 studies 
provided information on number of patients experiencing 
at least one grade 3/4 AE, although assessment of 
individual toxicities yielded similar results especially for 
non-hematological AEs. Finally, all included studies were 
designed to test primarily the efficacy of new systemic 
treatments and the outcome measures included in our 
analysis of toxicity were not primary endpoints in any of 
the included studies. Collection and reporting of toxicity 
data in published RCTs can be suboptimal and variable 
[17-19] so that results of our analysis may not represent 
the true rates of toxicity even within the included studies. 
In conclusion, in addition to improvements in PFS, 
targeted drugs with companion diagnostics are associated 
with improved safety, and tolerability. 
MATERIALS AND METHODS
This analysis was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines. PRISMA checklist 
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is shown in Supplementary Figure 1.
Identification of studies
All targeted, anticancer agents approved by the 
US Food and Drug administration (FDA) between 
January 2000 and April 2014 for treatment of advanced 
or metastatic solid malignancies in adults were identified 
through the FDA website [20]. We excluded agents used 
in supportive cancer care, such as antiemetic drugs or 
bisphosphonates. We also excluded studies of cytotoxic 
chemotherapy, systemic radiation therapy, endocrine 
therapy and cancer vaccines. Drug labels of included 
agents were consulted for all referenced RCTs. We 
reviewed each article and identified those that used a 
companion diagnostic to select patients. We also reviewed 
the FDA website to evaluate those companion diagnostic 
tests approved for the specific indication.
Data extraction
Extracted data included the experimental agent, the 
diagnostic kit used in the study, the molecular alteration 
evaluated, tumor type, primary endpoint, use of cross-
over, type of FDA approval (regular or accelerated), 
reporting of quality of life, and year of publication. For 
efficacy outcomes, we extracted hazard ratios (HR) and 
their corresponding 95% confidence intervals (CI) for 
time-to-event endpoints including overall survival (OS) 
and/or progression-free survival (PFS). When data for 
PFS were not available, we extracted data for time to 
progression (TTP). For toxicity outcomes, the events of 
interest were the occurrence of death reported as being 
related to systemic treatment, treatment-discontinuation 
related to AEs and occurrence of grade 3/4 AEs. If a 
drug label did not report toxic death, it was assumed to 
be zero as such events are mandated to be reported to 
the FDA. For AEs, the number or proportion of patients 
with at least one grade 3/4 AE was collected. The 12 most 
commonly reported AEs were also assessed individually 
and included anemia, neutropenia, thrombocytopenia, 
diarrhea, vomiting, stomatitis, hypertension, fatigue/
asthenia, neuropathy as well as cardiovascular, pulmonary 
and skin AEs. Data were extracted by three authors (JE, 
VS and LD). Discrepancies were resolved by consensus.
Data synthesis
Drugs were assigned to one of two subgroups: 
targeted agents without companion diagnostic and 
targeted agents with available companion diagnostic. For 
the primary analysis, tumors with ubiquitous molecular 
alterations or mutations (e.g. c-kit in GIST or RET in 
medullary thyroid cancer) were included in the group of 
studies with companion diagnostics. To identify whether 
different levels of efficacy were derived from availability 
of companion diagnostics, we pooled HRs for OS and 
PFS for all available studies. A sensitivity analysis was 
conducted excluding studies conducted in conditions with 
ubiquitous activation of specific molecular pathways. 
For toxicity, we compared the rates of treatment-related 
death, treatment discontinuation due to toxicity and grade 
3/4 AEs between the companion diagnostic and non-
companion diagnostic groups. Sensitivity analyses were 
conducted to examine the effect of blinding (i.e. blinded 
or open-label studies) and type of control group (placebo-
only, active treatment or active treatment plus placebo) on 
toxicity outcomes.
Statistical analysis
Data were reported descriptively as means or 
medians together with respective standard deviations and 
ranges, respectively. When possible, data were combined 
into a meta-analysis using RevMan 5.3 analysis software 
(Cochrane Collaboration, Copenhagen, Denmark). 
Pooled estimates of HRs for OS and PFS were weighed 
by generic inverse variance and computed by random 
effects modeling [21, 22]. Pooled estimates of odds ratios 
(OR) of safety and tolerability endpoints were computed 
using different methods for toxic death, treatment-
discontinuation and grade 3/4 AEs. For toxic death where 
absolute event rates were less than 1%, the Peto one-
step odds ratio method was utilized [23]. For treatment-
discontinuation where there were low absolute event 
rates and substantial variability in relative effect-sizes, 
the Mantel-Haenszel odds ratio method was used [21]. 
Finally, for grade 3/4 AEs, the DerSimonian and Laird 
random-effects method was utilized and studies were 
weighted using the generic inverse variance approach [21, 
22]. Differences in the pooled estimates for companion 
and on-companion studies were evaluated using subgroup 
analysis as described by Deeks et al [21]. All statistical 
tests were two-sided, and statistical significance was 
defined as p < 0.05. No corrections were made for multiple 
testing.
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